Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous peripheral blood stem cell (PBSC) rescue is a cell therapy protocol utilized at the Masonic Cancer Center, University of Minnesota, for the treatment of high-risk neuroblastoma. The procedure involves the infusion of a patient's own hematopoietic stem cells, which are collected prior to the administration of myeloablative high-dose chemotherapy (typically involving agents like carboplatin, etoposide, and melphalan). The primary objective of the infusion is to "rescue" the patient's hematopoietic system by facilitating bone marrow reconstitution and accelerating the recovery of white blood cells, red blood cells, and platelets. This protocol is employed as a standard of care for pediatric patients who are ineligible for Children's Oncology Group (COG) clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous peripheral blood stem cell rescue.